Medication Pearl of the Day: Tisotumab Vedotin (Tivdak) for Cervical Cancer
Tisotumab vedotin, is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Medication Pearl of the Day: Tisotumab vedotin (Tivdak)
Indication: Tisotumab vedotin is a tissue factor (TF)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
- Dosage: For intravenous (IV) infusion only. The recommended dose of tisotumab vedotin is 2 mg/kg (up to a maximum of 200 mg) given as an IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
- Dosage form: For injection, 40 mg as a lyophilized cake or powder in a single-dose vial for reconstitution.
- Adverse Events (AEs): The most common (≥25%) AEs include laboratory abnormalities, decreased hemoglobin, fatigue, decreased lymphocytes, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival AEs, hemorrhage, decreased leukocytes, increased creatinine, dry eye, increased prothrombin international normalized ratio, prolonged activated partial thromboplastin time, diarrhea, and rash.
- Drug interaction: Strong CYP3A4 Inhibitors—closely monitor for tisotumab vedotin AEs.
- Mechanism of Action: Tisotumab vedotin, a TF-directed antibody drug conjugate, is a human immunoglobulin 1 directed against cell surface TF. TF is the primary initiator of the extrinsic blood coagulation cascade.
- Manufacturer: Seagen/Genmab